Patients with localized muscle-invasive bladder cancer (MIBC) who received radiation plus the immune checkpoint inhibitors (ICIs) durvalumab (Imfinzi) and tremelimumab (Imjudo) had durable responses that allowed for bladder ...
Feb 17, 2025
0
10
Head and neck cancers are the seventh most common type of cancer worldwide, according to the 2020 World Cancer Report. Smokers and drinkers, as well as those with HPV infections, are disproportionately affected.
Nov 22, 2024
0
26
Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that patients with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific mutations in the STK11 and/or KEAP1 tumor ...
Oct 11, 2024
0
63
Despite recent advances in the treatment of breast cancer, it remains the second leading cause of cancer death in the U.S. and worldwide. There is a continued need to improve treatment strategies and therapies that not only ...
Oct 1, 2024
0
39
People with limited-stage small cell lung cancer may benefit from adding immunotherapy to chemoradiation, but not if both treatments are given at the same time, new research finds. The results suggest that the timing of when ...
Sep 30, 2024
0
31
For patients with limited-stage small cell lung cancer, adjuvant therapy with durvalumab leads to significantly longer overall and progression-free survival, according to a study published online Sept. 13 in the New England ...
Sep 19, 2024
0
21
Professors Tom Powles and Peter Schmid recently delivered results from their phase three clinical trials during Sunday's Presidential Symposium to over 30,000 attendees at the European Society for Medical Oncology (ESMO) ...
Sep 16, 2024
0
37
The epidermal growth factor receptor tyrosine kinase inhibitor aumolertinib demonstrated improved progression-free survival compared to placebo without any significant new adverse reactions, according to data from the POLESTAR ...
Sep 11, 2024
0
21
Phase 2 results from the NeoCOAST-2 study have demonstrated that the combination of durvalumab with Dato-DXd yielded the highest pathological complete response rates among the tested regimens.
Sep 8, 2024
0
34
Many countries with national health care systems or payers such as insurance companies use cost-effectiveness analyses to decide whether to cover new medicines, balancing treatment costs with potential health benefits.
May 30, 2024
0
41
